Iranian Journal of Basic Medical Sciences

Iranian Journal of Basic Medical Sciences

Nose-to-brain drug delivery: A new frontier in targeted therapeutics

Articles in Press

Document Type : Review Article

Authors
SVVS Sai Sampath Karakavalasa
Rama Devi Korni
Department of Pharmaceutical Technology, Raghu College of Pharmacy, Visakhapatnam, Andhra Pradesh, India
10.22038/ijbms.2026.93677.20210
Abstract
Delivering therapeutics to the Central Nervous System (CNS) remains a major challenge in drug development, largely because the blood–brain barrier (BBB) limits brain exposure for most systemically administered agents. Among alternative delivery routes, intranasal administration has attracted significant interest because it leverages direct anatomical connections between the nasal cavity and the brain, thereby reducing reliance on BBB permeability. This review examines the nasal route, focusing on how olfactory and trigeminal neural pathways contribute to drug transport into the CNS. Rather than assuming a single dominant route, the relative roles of extracellular perineural diffusion, intracellular neuronal transport, perivascular movement, and cerebrospinal fluid–associated distribution are evaluated in light of existing experimental evidence. Key factors that limit or enhance intranasal brain delivery—including mucociliary clearance, local enzymatic activity, drug physicochemical properties, formulation design, and patient-specific variability—are discussed with attention to their practical implications. Recent advances in formulations, such as mucoadhesive and in situ gelling systems, particulate and lipid-based carriers, dendrimers, and stimuli-responsive platforms, are reviewed alongside developments in nasal delivery devices that influence regional deposition.
Keywords
Brain targeting
Central nervous system targeting
Intranasal
Nanoparticle
Nose-to-brain
Subjects
1. Pires PC, Santos AO. Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies. J Control Release 2018; 270: 89-100. 
2. Misra A, Kher G. Drug delivery systems from nose-to-brain. Curr Pharm Biotechnol 2012; 13: 2355-2379.
3. Bhunia S, Kolishetti N, Vashist A, Yndart Arias A, Brooks D, Nair M, et al. Drug delivery to the brain: recent advances and unmet challenges. Pharmaceutics 2023; 15: 2658.
4. Morofuji Y, Nakagawa S. Drug development for central nervous system diseases using in vitro blood-brain barrier models and drug repositioning. Curr Pharm Des 2020; 26: 1466-1485. 
5. Bors LA, Erdő F. Overcoming the blood–brain barrier: Challenges and tricks for CNS drug delivery. Sci Pharm 2019; 87: 6.
6. Zhang RX, Dong K, Wang Z, Miao R, Lu W, Wu XY. Nanoparticulate drug delivery strategies to address intestinal cytochrome P450 CYP3A4 metabolism towards personalized medicine. Pharmaceutics 2021; 13: 1261. 
7. Mittal D, Ali A, Md S, Baboota S, Sahni JK, Ali J. Insights into direct nose-to-brain delivery: Current status and future perspective. Drug Deliv 2013; 21: 75-86.
8. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000; 11: 1-18. 
9. Sobiesk JL, Munakomi S. Anatomy, head and neck, nasal cavity. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025.
10. Dahl R, Mygind N. Anatomy, physiology and function of the nasal cavities in health and disease. Adv Drug Deliv Rev 1998; 29: 3-12. 
11. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv Drug Deliv Rev 2012; 64: 614-628.
12. Dhuria SV, Hanson LR, Frey WH 2nd. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci 2010; 99: 1654-1673.
13. Pardeshi CV, Belgamwar VS. Direct nose-to-brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: An excellent platform for brain targeting. Expert Opin Drug Deliv 2013; 10: 957-972. 
14. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH 2nd. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004; 127: 481-496.
15. Alwali B, Parumasivam T, Al-Tabakha MM. Intranasal drug delivery: Unlocking the nose-to-brain route for central nervous system therapies. Int J Pharm X 2026; 11: 100521. 
16. D’Souza AA, DiFrancesco V, Yang A, Bleier BS, Amiji MM. Differential targeting of olfactory epithelium and respiratory epithelium in nose-to-brain drug delivery. Expert Opin Drug Deliv 2026; 23: 17-36.
17. Kiss AL, Botos E. Endocytosis via caveolae: Alternative pathway with distinct cellular compartments to avoid lysosomal degradation? J Cell Mol Med 2009; 13: 1228-1237.  
18. Wang Z, Tiruppathi C, Cho J, Minshall RD, Malik AB. Delivery of nanoparticle: Complexed drugs across the vascular endothelial barrier via caveolae. IUBMB Life 2011; 63: 659-667.  
19. Hui T, Haibin W, Huaqing C. Macropinocytosis: Molecular mechanisms and regulation. Curr Opin Cell Biol 2025; 95: 102563. 
20. Detampel P, Tehranian S, Mukherjee P, Foret M, Fuerstenhaupt T, Darbandi A, et al. Caveolin-initiated macropinocytosis is required for efficient silica nanoparticles’ transcytosis across the alveolar epithelial barrier. Sci Rep 2022; 12: 9474.
21. Ju Y, Guo H, Edman M, Hamm-Alvarez SF. Application of advances in endocytosis and membrane trafficking to drug delivery. Adv Drug Deliv Rev 2020; 157: 118-141.
22. D’Souza AA, DiFrancesco V, Yang A, Bleier BS, Amiji MM. Differential targeting of olfactory epithelium and respiratory epithelium in nose-to-brain drug delivery. Expert Opin Drug Delivery 2026; 23: 17-36. 
23. Merkus FW, Verhoef JC, Schipper NG, Marttin E. Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev 1998; 29: 13-38.
24. Gizurarson S. Anatomical and histological factors affecting intranasal drug and vaccine delivery. Curr Drug Deliv 2012; 9: 566-582.
25. Erdő F, Bors LA, Farkas D, Bajza Á, Gizurarson S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res Bull 2018; 143: 155-170.
26. Illum L. Nasal drug delivery: New developments and strategies. Drug Discov Today 2002; 7: 1184-1189.
27. Ugwoke MI, Verbeke N, Kinget R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J Pharm Pharmacol 2001; 53: 3-21.
28. Djupesland PG. Nasal drug delivery devices: Characteristics and performance in a clinical perspective—a review. Drug Deliv Transl Res 2013; 3: 42-62.
29. Illum L. Nasal drug delivery—possibilities, problems and solutions. J Control Release 2003; 87: 187-198.
30. Gizurarson S. The relevance of nasal physiology to the design of drug absorption studies. Adv Drug Deliv Rev 1993; 11: 329-347. 
31. Lochhead JJ, Wolak DJ, Pizzo ME, Thorne RG. Rapid transport within cerebral perivascular spaces underlies widespread tracer distribution in the brain after intranasal administration. J Cereb Blood Flow Metab 2015; 35: 371-381.
32. Qiu Y, Huang S, Peng L, Yang L, Zhang G, Liu T, et al. The nasal–brain drug delivery route: Mechanisms and applications to central nervous system diseases. MedComm 2025; 6: e70213.
33. Hanson LR, Frey WH 2nd. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008; 9: S5.
34. Pires A, Fortuna A, Alves G, Falcão A. Intranasal drug delivery: How, why and what for? J Pharm Pharm Sci 2009; 12: 288-311.
35. Chatterjee B, Gorain B, Mohananaidu K, Sengupta P, Mandal UK, Choudhury H. Targeted drug delivery to the brain via intranasal nanoemulsion: Available proof of concept and existing challenges. Int J Pharm 2019; 565: 258-268.
36. Li H, Shen X, Zhang B, Li Y, Alexander C, Harvey P, et al. Brain-targeted intranasal delivery of biologics: a perspective for Alzheimer’s disease treatment. RSC Pharm 2025; 2: 1323.
37. Gagliardi M, Chiarugi S, De Cesari C, Di Gregorio G, Diodati A, Baroncelli L, et al. Crosslinked chitosan nanoparticles with muco-adhesive potential for intranasal delivery applications. Int J Mol Sci 2023; 24: 6590.
38. Hua S. Advances in nanoparticulate drug delivery approaches for sublingual and intranasal administration. Front Pharmacol 2019; 10: 1328.
39. Thakkar HP, Singh N, Yadav D, Gupta S. Chitosan-based mucoadhesive formulations for intranasal drug delivery: A review. Int J Biol Macromol 2021; 187: 273-290. 
40. Chen Y, Liu Q, Chen J, Chen C, Chen X. Mucoadhesive nanoparticles for nose-to-brain drug delivery: Current strategies and challenges. Pharmaceutics 2022; 14: 2420. 
41. Ruel-Gariepy E, Leroux JC. In situ-forming hydrogels—review of temperature-sensitive systems. Eur J Pharm Biopharm 2004; 58: 409-426. 
42. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 1983; 15: 25-35. 
43. Gao H, Yang Z, Zhang S, Cao S, Shen S, Pang Z, et al. Ligand-modified nanoparticles increase brain drug delivery for Parkinson’s disease. Pharm Res 2010; 27: 2303-2314.
44. Das M, Sarma A, Baruah H, Basak D. Insight into central nervous system targeted nanostructured lipid carriers via the nose-to-brain pathway. RSC Pharm 2024; 1: 904-927.
45. Sharma S, Gauba P, Tyagi A, Dang S. Chitosan-modified polymeric nanoparticles for the nose-to-brain drug delivery of paroxetine: An in vitro and in vivo evaluation. Nanoscale 2024; 16: 16485-16499. 
46. Koo J, Lim C, Oh KT. Recent advances in intranasal administration for brain-targeting delivery: A comprehensive review of lipid-based nanoparticles and stimuli-responsive gel formulations. Int J Nanomedicine 2024; 19: 1767-1807.
47. Naki T, Peter S, Alven S. Polymeric nanocarrier-based drug formulations for enhancing nose-to-brain delivery. Pharmaceutics 2025; 17: 1242.
48. Alberto M, Paiva-Santos AC, Veiga F, Pires PC. Lipid and polymeric nanoparticles: Successful strategies for nose-to-brain drug delivery in the treatment of depression and anxiety disorders. Pharmaceutics 2022; 14: 2742.
49. Sonvico F, Clementino A, Buttini F, Colombo G, Pescina S, Stanisçuaski Guterres S, et al. Surface-modified nanocarriers for nose-to-brain delivery: from bioadhesion to targeting. Pharmaceutics 2018; 10: 34. 
50. Maher R, Moreno-Borrallo A, Jindal D, Mai BT, Ruiz-Hernandez E, Harkin A, et al. Intranasal polymeric and lipid-based nanocarriers for CNS drug delivery. Pharmaceutics 2023; 15: 746.
51. Kendre PN, Kayande DR, Jain SP, Malge TG, Zadpe NN, Prajapati BG. Polymeric nanoparticles: Prospective on the synthesis, characterization and applications in nose-to-brain drug delivery. Curr Nanoscience 2023; 19: e290922209276. 
52. Awad R, Avital A, Sosnik A. Polymeric nanocarriers for nose-to-brain drug delivery in neurodegenerative diseases and neurodevelopmental disorders. Acta Pharm Sin B 2023; 13: 1866-1886.
53. Gabold B, Adams F, Brameyer S, Jung K, Ried CL, Merdan T, et al. Transferrin-modified chitosan nanoparticles for targeted nose-to-brain delivery of proteins. Drug Deliv Transl Res 2023; 13: 822-838. 
54. Agrawal M, Saraf S, Saraf S, Dubey SK, Puri A, Gupta U, et al. Stimuli-responsive in situ gelling system for nose-to-brain drug delivery. J Control Release 2020; 327: 235-265.
55. Najjari Z, Sadri F, Varshosaz J. Smart stimuli-responsive drug delivery systems in spotlight of COVID-19. Asian J Pharm Sci 2023; 18: 100873.
56. Corazza E, di Cagno MP, Bauer-Brandl A, Abruzzo A, Cerchiara T, Bigucci F, et al. Drug delivery to the brain: in situ gelling formulation enhances carbamazepine diffusion through nasal mucosa models with mucin. Eur J Pharm Sci 2022; 179: 106294.
57. Singh J, Nayak P. pH-responsive polymers for drug delivery: Trends and opportunities. J Polym Sci 2023; 61: 2828-2850.
58. Mura P, Maestrelli F, Cirri M. In situ gelling systems for nasal drug delivery: Recent advances and future perspectives. J Drug Deliv Sci Technol 2024; 94: 105478.
59. Katare P, Patel A, Chaudhari S. Nasal drug delivery systems and devices: An overview of formulation strategies, device design, and clinical applications. ACS Chem Health Saf 2024; 31: 145-158. 
60. Tanna V, Vora A, Shah P, Nair AB, Shah J, Sawarkar SP. PLGA nanoparticles based mucoadhesive nasal in situ gel for enhanced brain delivery of Topiramate. AAPS PharmSciTech 2024; 25: 205.
61. Sharma S, Tyagi A, Dang S. Nose-to-brain delivery of transferrin-conjugated PLGA nanoparticles for clonidine. Int J Biol Macromol 2023; 252: 126471.
62. Omidian H, Wilson RL. PLGA-based strategies for intranasal and pulmonary applications. Pharmaceutics 2025; 17: 207.
63. Drath I, Richter F, Feja M. Nose-to-brain drug delivery: From bench to bedside. Transl Neurodegener 2025; 14: 23.
64. Keller LA, Merkel O, Popp A. Intranasal drug delivery: Opportunities and toxicologic challenges during drug development. Drug Deliv Transl Res 2022; 12: 735-757.
65. Maaz A, Blagbrough IS, De Bank PA. In vitro evaluation of nasal aerosol depositions: an insight for direct nose-to-brain drug delivery. Pharmaceutics 2021; 13: 1079.
66. Lobo S, Xi Z, Das D, Hadzimichalis NM, Creek JA. Intranasal delivery: Formulation factors and insights into user experience. AAPS PharmSciTech 2025; 26: 179.
67. Safarov R, Fedotova O, Uvarova A, Gordienko M, Menshutina N. Review of intranasal active pharmaceutical ingredient delivery systems. Pharmaceuticals (Basel) 2024; 17: 1180.
68. Fortuna A, Alves G, Serralheiro A, Sousa J, Falcão A. Intranasal delivery of systemic-acting drugs: Small-molecules and biomacromolecules. Eur J Pharm Biopharm 2014; 88: 8-27.
69. Barve MH, Shardul PK, Munne SS, Bendale AR, Naphade V, Pathan VT, et al. Metered dose inhalers (MDIs) for high-performance pulmonary drug delivery in assistance to nanotechnology. Biosci Biotech Res Asia 2023; 20: 457-468.
70. Djupesland PG, Messina JC, Mahmoud RA. Breath powered nasal delivery: A new route to rapid headache relief. Headache 2013; 53: 72-84.
71. Liu Y, Wu D. Bi-directional nasal drug delivery systems: A scoping review of nasal particle deposition patterns and clinical application. Laryngoscope Investig Otolaryngol 2023; 8: 1484-1499.
72. Palmer JN, Adappa ND, Chandra RK, Davis GE, Mahdavinia M, Messina J, et al. Efficacy of EDS-FLU for chronic rhinosinusitis: Two randomized controlled trials (ReOpen1 and ReOpen2). J Allergy Clin Immunol Pract 2024; 12: 1049-1061.
73. Ge Y, Xu X, Cao M, Liu B, Wang Y, et al. Nasal drug delivery and nose-to-brain delivery technology development status and trend analysis: Based on questionnaire survey and patent analysis. Pharmaceutics 2024; 16: 929.
74. Wei S, Zhai Z, Kong X, Wu C, Zhu B, Zhao Z, Zhang X. Review of nasal drug delivery systems: strategies to enhance intranasal drug absorption and delivery efficiency. Int J Pharm 2025; 676: 125584.
75. Wu X, Zang R, Qiu Y, Zhang Y, Peng J, Cheng Z, et al. Intranasal drug delivery technology in the treatment of central nervous system diseases: Challenges, advances, and future research directions. Pharmaceutics 2025; 17: 775.
76. Danga N, Korni RD, Laveti V, Sampath KSVVS, Panda J, Pinagadi PK. Formulation and characterization of paroxetine hydrochloride nasal gel: An innovative approach. Int J Pharm Investig 2025; 15: 953-960.
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 22 September 2026